ATE290592T1 - Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis - Google Patents

Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis

Info

Publication number
ATE290592T1
ATE290592T1 AT99116671T AT99116671T ATE290592T1 AT E290592 T1 ATE290592 T1 AT E290592T1 AT 99116671 T AT99116671 T AT 99116671T AT 99116671 T AT99116671 T AT 99116671T AT E290592 T1 ATE290592 T1 AT E290592T1
Authority
AT
Austria
Prior art keywords
human
hepatitis virus
immunodominant epitopes
cell immunodominant
amino acids
Prior art date
Application number
AT99116671T
Other languages
English (en)
Inventor
Geert Leroux-Roels
Robert Deleys
Geert Maertens
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8214764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE290592(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE290592T1 publication Critical patent/ATE290592T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99116671T 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis ATE290592T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93402718 1993-11-04

Publications (1)

Publication Number Publication Date
ATE290592T1 true ATE290592T1 (de) 2005-03-15

Family

ID=8214764

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99116672T ATE274578T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
AT94931000T ATE236981T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
AT99116671T ATE290592T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT99116672T ATE274578T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
AT94931000T ATE236981T1 (de) 1993-11-04 1994-10-28 Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis

Country Status (11)

Country Link
US (4) US6555114B1 (de)
EP (4) EP0992580B1 (de)
JP (2) JPH09504534A (de)
AT (3) ATE274578T1 (de)
AU (1) AU698878B2 (de)
CA (1) CA2175692A1 (de)
DE (3) DE69434295T2 (de)
DK (2) DK0725824T3 (de)
ES (2) ES2239819T3 (de)
PT (2) PT725824E (de)
WO (1) WO1995012677A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6555114B1 (en) * 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
DE69517521T2 (de) * 1994-04-08 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
WO1999024466A2 (en) * 1997-11-06 1999-05-20 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
JP2002512370A (ja) 1998-04-17 2002-04-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 還元剤を用いる改良された免疫診断アッセイ
AU3714499A (en) * 1998-05-14 1999-11-29 Pasteur Merieux Serums Et Vaccins Hepatitis c virus mimotopes
NZ508812A (en) * 1998-06-12 2002-11-26 Aventis Pasteur Peptides for the prevention or treatment of HIV
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
NZ508797A (en) * 1998-06-24 2004-02-27 Innogenetics N Particles of HCV envelope proteins: use for vaccination
EP1105496B1 (de) 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifizierte hcv peptid-impfstoffe
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
RU2286172C2 (ru) * 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
JP2004522415A (ja) * 2000-09-01 2004-07-29 エピミューン インコーポレーティッド Ｈｌａ結合ペプチドおよびその使用方法
GB0026094D0 (en) * 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US8129349B2 (en) * 2000-10-27 2012-03-06 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002252856A1 (en) 2001-04-24 2002-11-05 Innogenetics N.V. Expression of core-glycosylated hcv envelope proteins in yeast
FR2825093B1 (fr) * 2001-05-28 2003-07-18 Bio Merieux Polypeptide reagissant avecles anticorps de patients infectes par vhc et utilisations
FR2825363A1 (fr) * 2001-05-31 2002-12-06 Bio Merieux Polypeptides reagissant avec les anticorps de patients infectes par vhc et utilisations
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
WO2003051912A2 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2004041842A2 (en) * 2002-05-16 2004-05-21 The General Hospital Corporation Epitopes of hepatitis c virus
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CA2491508A1 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains
EP1558283A2 (de) * 2002-11-08 2005-08-03 Innogenetics N.V. E1 und ns3 peptide enthaltende hcv impfstoffzusammensetzungen
EP1583773A1 (de) * 2003-01-07 2005-10-12 Biomerieux Hepatitis c f' polypeptide, epitope und dessen diagnostische und therapeutische anwendungen
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US20080112977A1 (en) * 2004-07-03 2008-05-15 Mogam Biotechnology Research Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
CU23470A1 (es) * 2004-08-11 2009-12-17 Ct Ingenieria Genetica Biotech Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
ES2349153T3 (es) * 2004-09-29 2010-12-28 The Administrators Of The Tulane Educational Fund Inhibidores del virus de la hepatitis c.
SG156652A1 (en) 2004-10-18 2009-11-26 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis c infection
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
WO2007041861A1 (en) * 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
JP2009541325A (ja) * 2006-06-20 2009-11-26 メタプロテオミクス， エルエルシー テトラヒドロ−イソアルファ酸に基づくタンパク質キナーゼ調節癌治療
CA2654271A1 (en) * 2006-06-28 2008-01-03 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
ES2303496B1 (es) * 2008-02-21 2009-07-07 Fundacion Para El Estudio De Las Hepatitis Virales Metodo analitico perfeccionado para la deteccion de hepatitis c oculta, aplicaciones del mismo y su correspondiente kit de diagnostico.
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
US8741311B2 (en) 2009-03-27 2014-06-03 Academia Sinica Methods and compositions for immunization against virus
WO2010112733A1 (fr) * 2009-03-30 2010-10-07 bioMérieux Support solide de détection du vhc
JP5930967B2 (ja) 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
EP2646459B1 (de) 2010-12-02 2020-01-08 Bionor Immuno AS Peptidgerüstentwurf
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
EP2859011B1 (de) 2012-06-06 2019-12-11 Bionor Immuno AS Peptide aus viralen proteinen zur verwendung als immunogene oder nachweisreagenzien
WO2014129412A1 (ja) * 2013-02-19 2014-08-28 国立大学法人神戸大学 免疫原性ポリペプチド表層発現ビフィズス菌
EP2970947A4 (de) 2013-03-14 2016-10-12 Abbott Lab Rekombinante hcv-ns3-antigene und mutanten für den verbesserten nachweis von antikörpern
EP3564384A1 (de) * 2013-03-14 2019-11-06 Abbott Laboratories Monoklonale antikörper gegen hcv-core lipid-bindender domäne
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
US10407508B2 (en) 2013-07-08 2019-09-10 Nanjing Legend Biotech., Ltd. Compositions and methods for increasing protein half-life in a serum
CN109963587A (zh) 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
US12048742B2 (en) 2018-03-16 2024-07-30 The Governors Of The University Of Alberta Hepatitis C virus peptide compositions and methods of use thereof
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
CN113454215A (zh) * 2019-01-25 2021-09-28 森迪生物科学公司 用于控制蛋白质功能的融合构建体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
AU7679491A (en) * 1990-04-04 1991-10-30 Protos, Inc. Hepatitis c virus protease inhibitors
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
KR0181517B1 (ko) 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
EP0485209A1 (de) 1990-11-08 1992-05-13 Immuno Japan Inc. Mit Non-A Non-B Hepatitis Virus verwandtes Antigen, Aufspürsysteme für Antikörper, Polynukleotide und Polypeptide
AU648912B2 (en) 1991-06-13 1994-05-05 Dade International Inc. Immunoassay for non-A non-B hepatitis
CA2110058C (en) * 1991-06-24 2001-09-25 David Y. Chien Hepatitis c virus (hcv) polypeptides
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
US5428145A (en) 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
EP0600009A4 (de) * 1991-08-21 1995-03-01 Abbott Lab Hepatitis c-nachweistest unter benutzung rekombinanter antigene der ns1-region.
HU227510B1 (en) * 1991-09-13 2011-07-28 Novartis Vaccines & Diagnostic Immunoreactive hepatitis c virus polypeptide compositions
EP0642666B2 (de) * 1991-09-16 2004-08-11 Abbott Laboratories Verfahren zur detektion von hepatitis c
DE69332045T2 (de) * 1992-02-04 2002-10-17 Chiron Corp., Emeryville Hepatistherapeutikum
CA2102301C (en) * 1992-03-06 2008-09-16 Robert De Leys Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
AU685521B2 (en) * 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US6555114B1 (en) * 1993-11-04 2003-04-29 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5543657A (en) * 1994-10-07 1996-08-06 International Business Machines Corporation Single layer leadframe design with groundplane capability

Also Published As

Publication number Publication date
EP0992580B1 (de) 2005-03-09
EP0992580A3 (de) 2000-08-09
ES2239819T3 (es) 2005-10-01
EP0992581B2 (de) 2011-05-25
EP0992581B1 (de) 2004-08-25
EP0992581A2 (de) 2000-04-12
EP0725824A1 (de) 1996-08-14
AU7993294A (en) 1995-05-23
PT725824E (pt) 2003-08-29
ES2197170T3 (es) 2004-01-01
DK0725824T3 (da) 2003-08-11
EP0725824B1 (de) 2003-04-09
AU698878B2 (en) 1998-11-12
DE69434295T2 (de) 2006-02-16
DE69433971T2 (de) 2005-09-08
DE69432475D1 (de) 2003-05-15
EP0992581A3 (de) 2001-03-07
EP0992580A2 (de) 2000-04-12
JP2004194668A (ja) 2004-07-15
CA2175692A1 (en) 1995-05-11
DK0992580T3 (da) 2005-07-11
US20040047877A1 (en) 2004-03-11
ATE274578T1 (de) 2004-09-15
DE69432475T2 (de) 2004-03-04
US6555114B1 (en) 2003-04-29
DE69433971D1 (de) 2004-09-30
JPH09504534A (ja) 1997-05-06
EP0979867A3 (de) 2007-06-13
WO1995012677A3 (en) 1995-07-27
DE69434295D1 (de) 2005-04-14
WO1995012677A2 (en) 1995-05-11
US6689368B1 (en) 2004-02-10
EP0979867A2 (de) 2000-02-16
PT992580E (pt) 2005-07-29
US6613333B1 (en) 2003-09-02
ATE236981T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
ATE274578T1 (de) Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
DE69232871D1 (de) Polypeptide des hepatitis c-virus (hiv)
EP0608261A4 (de) Zusammensetzung aus einem immunreaktiven hepatitis-c-virus-polypeptid.
ATE141946T1 (de) Hiv-2-virusvarianten
NO892251L (no) Fremgangsmaate ved fremstilling av kokkoidosevaksine ved rekombinante teknikker.
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE280227T1 (de) Epitope von stress proteinen
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
GB8625435D0 (en) Human apolipoprotein ai
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
DE69534296D1 (de) Sektretierter E1/E2 Hepatitis C Virus-Komplex erhalten aus C-terminal verkürzten Polypeptiden E1 und E2
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
ATE205220T1 (de) Hepatitis-a-impfstoff
DK204588D0 (da) Humane rhinoviruspeptider, fremgangsmaade til deres fremstilling samt vacciner med inhold af saadanne peptider
DE69328488D1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
EP0637631A3 (de) Hoch effiziente Expression eines Polypeptids, das eine modifizierte preS1-Region des grossen Hepatitis B-Virus-Antigens enthält.
ITFI920071A0 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vogeesndk
DE69416453D1 (de) HCV-Peptide und deren Verwendung
ATE290598T1 (de) Neue staphylokinase derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0992580

Country of ref document: EP

RZN Patent revoked